Unchecked drug price increases hit both patients and hospitals hard. Since 2008, brand name drugs prices have increased 127 percent compared with an 11 percent rise in consumer prices. These increases cut deep into both hospital budgets and services and undermine patient and community health, particularly when patients cannot afford to take their medicines. These increases are simply unsustainable. This week, we joined the Campaign for Sustainable Rx Pricing in support of policy principles designed to help find solutions to high drug prices. These solutions seek to preserve innovation and ensure affordability by increasing transparency, promoting competition and realizing more value. Rising drug prices, their impact and implications are also on the agenda next week at the AHA’s Annual Meeting as the focus of a May 2 Executive Briefing. The time for action is now. As much as anyone, the women and men who work in hospitals recognize the value of innovative, lifesaving medicines but a drug priced beyond our – or a patient’s reach – cannot save anyone’s life. 

Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The White House April 2 issued a proclamation implementing additional tariffs on certain patented pharmaceutical products and ingredients. The order imposes a…
Headline
The Centers for Medicare & Medicaid Services April 2 released a final rule on policy and technical changes to Medicare Advantage, the Medicare Prescription…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…